Table 4. Summary of the data including the receptors immunostain results and Fisher’s Exact tests’ p-values as the stains have been compared to the body mass index.
| Diagnosis | n | ER | PR | AR | BMI | ||||
|---|---|---|---|---|---|---|---|---|---|
| +n | +% | +n | +% | +n | +% | +n | +% | ||
| EEC | 36 | 35 | 97% | 35 | 97% | 35 | 97% | 25 | 69% |
| NEEC | 31 | 15 | 48% | 11 | 35% | 21 | 68% | 25 | 81% |
| SCA | 13 | 11 | 85% | 8 | 62% | 12 | 92% | 12 | 92% |
| CCCA | 6 | 0 | 0% | 0 | 0% | 3 | 50% | 5 | 83% |
| CS | 6 | 4 | 67% | 3 | 50% | 6 | 100% | 4 | 67% |
| DECA | 5 | 0 | 0% | 0 | 0% | 0 | 0% | 4 | 80% |
| MNCA | 1 | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| Met | 4 | 4 | 100% | 3 | 75% | 4 | 100% | 4 | 100% |
| All | 71 | 54 | 76% | 49 | 69% | 60 | 85% | 54 | 76% |
| 2x2 Contingency Table Values | Fisher’s Exact Test P-Values | ||||||||
| Positive | Negative | ER vs BMI | PR vs BMI | AR vs BMI | |||||
| EEC | ER | 35 | 1 | 0.003 | |||||
| PR | 35 | 1 | 0.003 | 0.003 | |||||
| AR | 35 | 1 | |||||||
| BMI | 25 | 11 | |||||||
| NEEC | ER | 15 | 16 | 0.0007 | |||||
| PR | 11 | 20 | 0.02 | 0.4 | |||||
| AR | 21 | 10 | |||||||
| BMI | 25 | 6 | |||||||
| Met | ER | 4 | 0 | 1 | |||||
| PR | 3 | 1 | 1* | 1* | |||||
| AR | 4 | 0 | |||||||
| BMI | 4 | 0 | |||||||
| All | ER | 54 | 17 | 0.5 | |||||
| PR | 49 | 22 | 1 | 0.3 | |||||
| AR | 60 | 11 | |||||||
| BMI | 54 | 17 | |||||||
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; +, positive reaction; EEC, endometrial endometrioid cancer; NEEC, non-endometrioid endometrial cancers which includes: SCA, serous carcinoma; CCCA, clear cell carcinoma; CS, carcinosarcoma; DECA, dedifferentiated endometrial carcinoma; and MNCA, mesonephric like carcinoma; Met, metastatic carcinoma; BMI, body mass index (kg/m2), BMI ≥30 as positive, BMI <30 as negative
*, the statistical test did net return any result because of the two zeros, therefor the p-value is assumed as "1" since both sets of data are identical.